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Antipsychotic drugs have thus far focused on dopaminergic antagonism at the D2 recep-
tors, as counteracting the hyperdopaminergia in nigrostriatal and mesolimbic projections
has been considered mandatory for the antipsychotic action of the drugs. Current drugs
effectively target the positive symptoms of psychosis such as hallucinations and delusions
in the majority of patients, whereas effect sizes are smaller for negative symptoms and
cognitive dysfunctions. With the understanding that neurocognitive dysfunction associ-
ated with schizophrenia have a greater impact on functional outcome than the positive
symptoms, the focus in pharmacotherapy for schizophrenia has shifted to the potential
effect of future drugs on cognitive enhancement. A major obstacle is, however, that the
biological underpinnings of cognitive dysfunction remain largely unknown. With the avail-
ability of increasingly sophisticated techniques in molecular biology and brain imaging,
this situation is about to change with major advances being made in identifying the neu-
ronal substrates underlying schizophrenia, and putative pro-cognitive drug targets may be
revealed. In relation to cognitive effects, this review focuses on evidence from basic neu-
roscience and clinical studies, taking two separate perspectives. One perspective is the
identification of previously under-recognized treatment targets for existing antipsychotic
drugs, including myelination and mediators of inflammation. A second perspective is the
development of new drugs or novel treatment targets for well-known drugs, which act on
recently discovered treatment targets for cognitive enhancement, and which may comple-
ment the existing drugs. This might pave the way for personalized treatment regimens for
patients with schizophrenia aimed at improved functional outcome.The review also aims at
identifying major current constraints for pro-cognitive drug development for patients with
schizophrenia.
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INTRODUCTION
Schizophrenia is a severe mental disorder with typical onset in the
late teens or early adulthood and a chronically relapsing remitting
course in the majority of cases (1). Schizophrenia remains a lead-
ing cause of years lived with disability (2), and active psychosis has
been ranked among the most disabling disorders by severity in the
general population (3).
The clinical picture of schizophrenia is heterogeneous, but in
the vast majority of patients, cognitive dysfunctions are present
with adverse impact on daily functioning (1). Antipsychotic drugs
have for six decades been a cornerstone in the treatment of the
disorder but a fundamental limitation is their small effect sizes
in the cognitive symptom domain (4) as the drugs are primar-
ily effective against the positive symptoms of psychosis including
hallucinations and delusions (4). Since the serendipitous discov-
ery of chlorpromazine’s antipsychotic properties, dopaminergic
antagonism has served as a template for all subsequent antipsy-
chotics through counteracting subcortical hyperdopaminergia (5).
The drugs following chlorpromazine are usually classified as typi-
cal or first generation antipsychotics (FGAs), whereas clozapine
much later became the prototype for the atypical or second-
generation antipsychotic (SGA) drugs that were developed in the
1990s onward (4, 6). Only modest differences in antipsychotic effi-
cacy have been found among FGAs and SGAs (7), but the SGAs
seem to display a broader therapeutic repertoire including also
pro-cognitive properties, although of a small magnitude (8). Phar-
macologically, the FGAs have strong affinities for the dopamine
type 2 (D2) receptor, whereas the SGAs are characterized by a
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more pronounced 5-HT2A antagonism than FGAs, and a lower
potency for the D2 receptor (9, 10). The narrow focus on the
dopaminergic system and striatal hyperdopaminergia in partic-
ular has most likely contributed to the limited evolvement of
more effective drug treatment options as it has become increas-
ingly clear that dopaminergic disturbances account for only parts
of the clinical picture (particularly for positive symptoms) (11–
13), and hyperdopaminergia is not present in all schizophrenia
patients (14).
Recognizing the large impact that the schizophrenia associ-
ated cognitive dysfunctions have on functional outcome (15, 16),
the efforts to improve the pharmacological treatment have moved
toward cognitive enhancement, and pro-cognitive effects have
been proposed as primary targets in future drug studies (17, 18).
A major obstacle restricting hypothesis-driven pro-cognitive drug
development has been the lacking knowledge of the structural
and functional brain alterations underlying cognitive dysfunction
in patients with schizophrenia (19, 20). Major scientific advances
in unveiling the neurobiology of schizophrenia have emerged in
recent years, however. The knowledge of transmitter dysfunc-
tions especially is widened (21), accompanied by evidence of
disturbances of myelination and inflammation/immunology in
the pathophysiology of schizophrenia (22, 23). Thus, going beyond
the neurotransmitter disturbances associated with schizophrenia,
the present work reviews the latest evidence on myelin alter-
ations, and the involvement of neuroinflammation/immunology
in schizophrenia, with putative relevance for pro-cognitive drug
effects in schizophrenia and related psychotic disorders. More-
over, these areas seem at least partly inter-related and the review
aims at integrating the evidence from key publications in a
joint model. Increased insight into the relevant functional and
structural alterations might pave the way for more efficacious,
targeted, and personalized pro-cognitive drug treatment oppor-
tunities aimed at improving real-world functioning. The review
focuses on both previously unknown treatment targets for exist-
ing antipsychotic drugs, and potentially novel pro-cognitive drugs
addressing extra-dopaminergic treatment targets, and gives an
update also commenting on current constraints of pro-cognitive
drug development for patients with schizophrenia.
COGNITIVE DYSFUNCTION IN PATIENTS WITH
SCHIZOPHRENIA
Cognitive function may be understood in terms of inter-related
complex neural networks, influenced by different neurotrans-
mitters, cytokines, and other substances including brain-derived
neurotropic factor (BDNF) acting as neuromodulators (24).
Cognitive deficits are viewed as core characteristics of schizo-
phrenia, with clinically significant cognitive impairments observed
in a large majority of patients, and most patients experience lower
cognitive functioning than would be expected from parental lev-
els of education (16, 25). Cognitive deficits are seen before the
development of psychosis (25–28), and cognitive decline and
intellectual stagnation have been suggested to constitute a risk
phenotype for developing schizophrenia (25). Furthermore, cog-
nitive deficits are relatively stable after psychotic breakthrough and
still present when the symptoms of psychosis have been treated
(29, 30). A general cognitive dysfunction across cognitive domains
is present, with additional selective deficits in working memory,
executive function, attention, verbal fluency, episodic memory,
and processing speed (15, 31). The effect size of the cognitive dys-
function compared to healthy subjects is close to 1.0 (32, 33), and
in several neurocognitive dimensions the impairment is between
1 and 2 SDs, indicating a clinically significant loss of function
(25, 34–37). Cognitive functioning has greater impact than pos-
itive psychotic symptoms in determining the patient’s real-world
functional outcome (15, 38–41), and relationships between more
specific cognitive domains and functional domains have also been
reported (38, 40, 42). Thus, cognitive impairment has been put
forward as the main target for novel treatment interventions in
schizophrenia (25).
A significant challenge has been to develop clinical meaningful
measures of cognitive dysfunction for pro-cognitive drug advance-
ment. A major contribution to establish a standardized and man-
ageable test battery for measuring cognition in schizophrenia
has been the development of the Measurement and Treatment
Research to Improve Cognition in Schizophrenia (MATRICS)
Consensus Cognitive Battery (MCCB) (43). The MCCB compos-
ite score has been suggested as the best outcome measure based
on findings of low practice effects, high test–retest reliability, and
good external validity (44), while a recent factor analysis identi-
fied a three factor model of processing speed, attention/working
memory, and learning as the best representations of data in this
particular study (45).
DOES ABNORMAL MYELINATION CAUSE COGNITIVE
DYSFUNCTIONS IN PATIENTS WITH SCHIZOPHRENIA?
Myelin, the main constituent of white matter, is essential for con-
trolling and regulating conduction velocities along axons and
thus the synchronicity of brain signals across different brain
regions, and for controlling synapse plasticity (46). Decreased
myelin integrity might accordingly alter normal signal trans-
duction. In the following, we will focus on one major line of
recent achievements in schizophrenia research, namely the rapidly
expanding knowledge of abnormal central nervous myelination
in patients with schizophrenia and the possibilities to prevent or
repair myelin pathology. White matter brain alterations and func-
tional connectivity problems that have been linked to cognitive
dysfunctions in schizophrenia will be briefly described, followed
by in-depth descriptions of new findings of myelin alterations
linked to cognition. Again, a major problem is to identify man-
ageable tests/measures of myelinization and myelin integrity that
can be used in drug discovery programs in a reliable way. Finally,
we will discuss candidate drug treatments counteracting deficits
of myelinization in patients with schizophrenia
WHITE MATTER CHANGES AND COGNITION
Several distinct alterations in gray and white matter are well
established for schizophrenia patients as a group (47). Reviews
of white matter tract pathology in patients with schizophrenia
[mostly studies based on voxel-based morphometry (VBM) and
diffusion tensor imaging (DTI)] have identified widespread and,
in many studies, progressive changes (47). A meta-analysis of
15 DTI studies by Ellison-Wright and Bullmore (48) identified
reductions (in all studies) of left frontal deep white matter and
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left temporal white matter. Thus, the authors suggested that two
different networks may be affected; one connecting the frontal
lobe with thalamus and cingulate gyrus, the other connecting the
temporal lobe with, e.g., insula, amygdala, hippocampus, and the
frontal lobe. A review by Walterfang et al. (49) of white mat-
ter pathology in patients with schizophrenia identified changes
in the left uncinate fasciculi as the most replicated finding, fur-
thermore that deficits of information processing was associated
with volume reductions in the uncinate and inferior longitudi-
nal fasciculi, anterior internal capsule, and corpus callosum (49).
White matter pathology related to cognition has also been found
in first-episode patients with psychosis. For example, Rigucci and
colleagues (50) reported a relationship between speed of process-
ing and visual memory and white matter fractional anisotropy
(FA) in fronto-temporal tracts. Focusing on intra-cortical white
matter, several clusters of superficial white matter (SWM) com-
posed of U-shaped fibers connecting neighboring gyri together
with intra-cortical axons and fibers from deep matter pathways
displayed reduced FA in a study comparing patients with schiz-
ophrenia to healthy controls. The correlations between SWM-
FA and cognition displayed in healthy controls were missing in
patients (51).
FUNCTIONAL CONNECTIVITY STUDIES
Recently, also related to myelination, the search for brain alter-
ations underlying the psychopathology of schizophrenia has refo-
cused to examine neuronal dysconnectivity, i.e., abnormal com-
munication between local and distributed neuronal circuits or
disrupted integration of brain activation (52–54). Fornito et al.
(53) reviewed data on brain connectivity, and concluded that
schizophrenia is associated with: (1) a widespread and possibly
context-independent connectivity deficits, (2) additional transient
states of hyper- and/or hypo-connectivity related to specific tasks.
Disturbed connectivity within the frontal lobes has been found
to be related to working memory and to executive functioning
(52, 54). This includes abnormal connectivity in fronto-parietal,
fronto-cerebellar, and fronto-hippocampal networks (52). Verbal
processing deficits have been shown to be related to circuits in
the language areas of the brain, particularly to fronto-temporal
dysfunction (52, 54). Indeed, theories have been developed con-
centrating on the effect of reduced executive cognitive control over
the language processing in the temporal lobes as central to the
development of the symptoms of psychosis, for instance auditory
verbal hallucination (55).
Of future interest may be the influence of antipsychotic drugs
on the dynamic interaction between large-scale cortical networks
related to resting and effort-mode states (56). Using fMRI, Hug-
dahl et al. (57) found overlapping activation in a large-scale net-
work to occur with a range of different cognitive tasks implicating
the prefrontal cortex [see also Ref. (58)] suggesting that effec-
tive cognitive processing would require down-regulation of the
resting-state network in situations with increasing demands for
the up-regulation of the effort-mode network, and that cognitive
impairment in schizophrenia may result from failure of network
up- and down-regulation dynamics. Thus, based on brain imaging
results, therapeutic agents inducing stabilization and, ideally, nor-
malization of large-scale cortical network dynamics could possibly
have pro-cognitive effects. However, thus far no drug has been
reported to enhance connectivity (52).
The major question related to the structural basis of functional
dysconnectivity was addressed in the review by Fornito et al. (53).
The authors concluded with major overlaps between functional
and structural findings, but also differences, which could at least
partly be caused by intrinsic problems of the methods of structural
measurements (see Measuring Myelination).
MEASURING MYELINATION
Several methodological issues need consideration regarding the
use of imaging techniques for myelin assessments. The DTI signal
may reveal changes in white matter integrity but has limitations
in identifying the exact nature of these changes, as the FA reflects
different processes like demyelination, axonal swelling, or atro-
phy, and is sensitive to confounding effects of fiber crossings (59).
In a recent review by Du and Öngür (60), two novel MR-based
approaches – diffusion tensor spectroscopy (DTS) and magne-
tization transfer ratio (MTR) – were reviewed as measures of
axonal diameter (DTS) and myelin volume (MTR). Combining
MTR with DTI, Palaniyappan et al. (61) recently showed that the
degree of FA reduction in areas with decreased myelin volume pre-
dicted impaired processing speed, leading the authors to suggest
that combined DTI/MTR could be used as a treatment measure in
the development of pro-cognitive drugs.
A study applying graph theory to analyze data from DTI com-
bined with MTR showed that patients with schizophrenia have a
weaker globally integrated structural brain network when com-
pared to healthy controls (62). The same study concluded that
the frontal hubs had a less central role than in healthy con-
trols, which is in accordance with a reduced structural capacity
to integrate information across brain regions. Moreover, a new
study combining DTI and resting-state fMRI comparing patients
with schizophrenia to healthy controls identified a selective dis-
ruption of brain connectivity among central hub regions with a
potential communication capacity reduction and brain dynamics
alterations (63).
MYELIN DEFICIENCIES IN SCHIZOPHRENIA
Compelling evidence from several different lines of research has,
in recent years, implicated dysfunctional myelin and oligoden-
drocytes, the cells responsible for wrapping myelin around neu-
ronal axons in the brain, in the pathology of schizophrenia and
related psychoses (22, 64–66). Sources of evidence include genetics
and pharmacogenetic studies, post-mortem studies, and as briefly
reviewed in the previous subsections of brain imaging studies,
particularly DTI studies.
Normal myelination starts in the late part of fetal life and occurs
most rapidly during the first 2 years after birth, but continues to
adulthood in a region- and brain matter-specific manner (22, 65,
67). Initial myelination occurs subcortically, thus increasing the
conduction velocities across different brain regions while leav-
ing the intra-cortical portion of the axon unmyelinated during
childhood (65). Interestingly, maturation of white matter in the
prefrontal cortex and in fronto-temporal tracts occurs later, in
late adolescence and early adult life, coinciding in time with the
peak age of schizophrenia onset (1). Possibly, disturbances in the
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maturation of myelin around the end of the myelination stage
could be one of the events contributing to the peak debut inci-
dence of schizophrenia in this age group (66). The prefrontal
cortex is one of the regions most robustly implicated in schizophre-
nia pathology, and working memory performance, which engages
this region, has been found to be positively associated with the
level of white matter maturation (67). Later intra-cortical myeli-
nation occurs for the most part in adulthood and is associated
with the refinement of cognitive functions and brain plasticity
(65). Importantly, myelination is a dynamic process, and oligo-
dendrocyte progenitor cells continue to differentiate throughout
life (68). In schizophrenia, intra-cortical myelin deficits seems to
be more pronounced than subcortical deficits, which have been
found to be more strongly associated with the duration of illness.
Indeed, evidence suggests that myelin integrity is closely related to
both cognitive functioning and to the symptoms of a variety of
psychiatric and neurological disorders (22, 46).
Alterations particularly in dopaminergic transmission (69, 70),
and also in the glutamatergic system, (11, 71) have been robustly
implicated in the pathology of schizophrenia for several decades.
Glutamatergic N -methyl-d-aspartate (NMDA) receptor antago-
nists, such as phencyclidine (PCP) and ketamine, have the poten-
tial to induce not only positive symptoms of psychosis but also
negative symptoms and cognitive dysfunction resembling those
seen in schizophrenia (11, 71). This has given rise to the NMDA
receptor hypofunction hypothesis of schizophrenia (21, 72). The
hypothesis has been extensively investigated in animal models but
several limitations related to how well evidence from preclinical
studies translate into schizophrenia patients have been pointed to
(72). Seemingly, paradoxically another model of schizophrenia-
related cognitive dysfunction is that of glutamatergic hyperactivity
(73). The model is based on other observations of increased pre-
frontal glutamate release following NMDA receptor antagonism.
The apparent paradoxical glutamate findings might be explained
by different NMDA receptor properties related to the different
locations and/or sub-compositions of the different NMDA recep-
tors as elaborated by Zhou et al. (74). Interestingly, there are several
points of convergence between myelin deficits and neurotrans-
mitter alterations. Firstly, glutamate is excitotoxic when in excess,
and oligodendrocyte progenitor cells display great vulnerability for
glutamatergic excitotoxicity (68). Increased glutamate levels have
been found in some phases of schizophrenia (75–77). Secondly,
there is emerging evidence that dysfunctional myelin and oligo-
dendrocytes could increase striatal dopamine levels, see Ref. (22)
for details. One example could be that if glutamatergic projections
from the prefrontal cortex to brainstem areas suffer from myelin
damage, this might lead to lower excitatory input at inhibitory
brainstem GABAergic interneurons, resulting in less inhibition of
dopaminergic mesolimbic projections and consequently striatal
hyperdopaminergia as outlined by Schwartz et al. (78).
MYELIN AS DRUG TARGET FOR PRESENT ANTIPSYCHOTICS
Animal studies suggest that myelin-protecting and oligodendrocyte-
stimulating properties may be a therapeutically relevant mech-
anism of action for at least some SGAs (61, 79, 80). In a DTI
study of schizophrenia patients in exacerbation, Garver et al.
(81) found increased diffusibility consistent with decreased myelin
integrity during acute psychosis. After initial examination, patients
were treated with the SGAs risperidone or ziprasidone, or the
FGA haloperidol, with partial restoration of myelin integrity after
4 weeks in the subgroup that responded to treatment. Bartzokis
et al. found higher volumes of intra-cortical myelin in schizo-
phrenia patients treated with oral risperidone compared to those
treated with the FGA fluphenazine decanoate (82). In a recent
study by the same group, the long acting injection formulation
of risperidone was associated with increased intra-cortical myelin
volume compared to the oral formulation of the same compound
(64). Myelin primarily consists of lipids, particularly cholesterol,
which are mainly synthesized de novo in the brain. Interestingly,
several antipsychotic agents have been demonstrated to directly
induce lipogenesis through the sterol regulatory element bind-
ing protein (SREBP) system, and these lipogenic effects have been
suggested to contribute to myelin-stimulating effects of antipsy-
chotic agents (83–85). In this regard, it is highly interesting that
clozapine, with its superior clinical efficacy, is also among the
antipsychotics associated with the most pronounced metabolic
adverse effects; in fact, a correlation between clinical improvement
and increase in serum lipid levels has repeatedly been demon-
strated (86–88). Summing up, a small but consistent body of
evidence indicates that some current SGAs have positive effects
on myelin volume, with possible distinctions among drugs and
drug formulations.
OTHER POTENTIAL “MYELIN-ENHANCING” TREATMENT OPTIONS
In a clinical randomized controlled trial (RCT) by Amminger
et al. (89), a markedly decreased progression rate to psychosis was
found in at risk subjects receiving high-dose polyunsaturated fatty
acids (PUFAs). PUFAs are involved in the myelination process,
and peripheral PUFA levels have been found to be decreased in
schizophrenia (90, 91). A recent DTI study in early-phase psy-
chosis patients found an association between level of PUFAs in
peripheral erythrocytes and white matter integrity (90). Possibly,
PUFA distribution is altered in patients at risk for psychosis, with a
link between PUFA levels and white matter integrity. Free radicals
can damage membrane PUFAs, and disturbances in fatty acids
and membrane phospholipid identified in patients with schizo-
phrenia may be caused by increased oxidative stress according to
a review by Yao and Keshavan (92). The same authors point to
disruption of antioxidative systems related to schizophrenia, with
reduced amounts of non-enzymatic plasma antioxidant compo-
nents [e.g., albumin, bilirubin, uric acid, ascorbic acid (vitamin
C), α-tocopherol (vitamin E)], see also the recent clinical study by
Zhang et al. demonstrating a reduced plasma total antioxidant sta-
tus in a sample of schizophrenia patients (93). Interestingly, PUFAs
also have mild anti-inflammatory effects, see Section “Additional
Drugs with Anti-Inflammatory Action as Add-on Treatments for
Patients with Schizophrenia.”
INFLAMMATION AND IMMUNOLOGY IN SCHIZOPHRENIA
IMPLICATING INFLAMMATORY SYSTEMS IN SCHIZOPHRENIA
Several findings point to a link between inflammatory processes
and the pathophysiology of schizophrenia: (1) activated periph-
eral inflammatory system and neuroinflammation in patients
with schizophrenia (94, 95), (2) evidence from genetic studies of
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correlation between schizophrenia and genes encoding for differ-
ent components of the immune system (96–98), (3) post-mortem
studies demonstrating up-regulated immune genes in the pre-
frontal cortex of patients with schizophrenia (99), (4) findings that
the raised risk of schizophrenia seen after maternal infections acts
via immunological mechanism (23), and (5) psychotic symptoms
and cognitive dysfunction caused by immunological neurological
syndromes (100), e.g., the interesting line of pathophysiological
evidence based on findings in autoimmune synaptic encephalitis
(limbic encephalitis), where antibody formation against NMDA
receptors is associated with a wide range of psychiatric symptoms,
in some patients also with syndromes resembling schizophrenia
(100). Binding of NMDA antibodies has been found predomi-
nantly in the hippocampus (101). Also, in systemic autoimmune
disorders such as systemic lupus erythematosus (SLE), patients
can suffer from various psychiatric syndromes, but the patho-
physiology has yet to be characterized in detail (102). A recent
remarkable finding is that the levels of soluble receptors for the
pro-inflammatory cytokine tumor necrosis factor (TNF)-α cor-
relates with function in patients with schizophrenia compared to
healthy individuals (103), the same study also found increased
levels of TNF-α in the treatment resistant group compared to
treatment responders.
In the following sections, we highlight some of the main
findings related to inflammation/immunology and schizophrenia,
with the specific purpose of evaluating the status of immune-
modulating treatment with cognitive-enhancing effects.
CYTOKINES
In the context of inflammatory changes in schizophrenia, the
majority of findings stem from the innate system, but components
of the adaptive immunology system have also been implicated.
The macrophages of the innate system induce the release of acute-
phase proteins [e.g., C-reactive protein (CRP) from hepatocytes]
as well as producing and releasing cytokines (97), all markers of
inflammation (104). Cytokines are also produced by peripher-
ally activated endothelial cells and monocyte-derived dendritic
cells (97).
PERIPHERAL INFLAMMATORY FINDINGS IN SCHIZOPHRENIA
Multiple studies have shown low-grade disturbances in the periph-
eral inflammatory system in patients with schizophrenia, see
recent reviews (105–107). Pro-inflammatory changes include ele-
vated serum measures of pro-inflammatory cytokines [interleukin
(IL)-1β, IL-6, IL-8, TNF-α] and other pro-inflammatory factors
[prostaglandin E2 (PGE2), CRP] and elevated monocyte counts
and activated immune cells have been associated with schizophre-
nia (108). Interestingly, some cytokines [IL-12, IFN-γ, TNF-α,
soluble IL-2 receptor (sIL-2R)] may be trait markers for schiz-
ophrenia, while others are raised during phases of intensified
symptoms (IL-1β, IL-6, and TGF-β) (106, 108). Furthermore,
some anti-inflammatory substances are elevated in subgroups
of patients with schizophrenia [soluble IL-1 receptor antagonist
(sIL-1RA), soluble IL-2 receptor antagonist (sIL-2RA), soluble
TNF receptors (sTNFRs)1, sTNFR2 (109), IL-10 (a cytokine with
anti-inflammatory properties), and transforming growth factor
(TGF)-β] (105). A review (110) identified decreased levels of IL-2
in patients with schizophrenia. IL-2 serves important functions in
T-cell-mediated immunologic reactions. Although the findings of
disturbances in the peripheral inflammatory system are not with-
out inconsistencies, and the measurements of cytokines are sensi-
ble to a wide range of confounders (e.g., the influence of antipsy-
chotic medication and metabolic status), there is firm evidence for
a mixed picture of peripheral pro- and anti-inflammatory changes
in a large proportion of patients with schizophrenia.
CENTRAL INFLAMMATORY FINDINGS IN PATIENTS WITH
SCHIZOPHRENIA
Brain neuroinflammation, in contrast to inflammation in other
parts of the body, does not lead to leukocyte recruitment, but
is characterized by activated microglia, the mononuclear phago-
cytes of the brain (111). Microglia develop from primitive myeloid
progenitors, and have various roles in the developing human brain
including synaptic pruning, remodeling of axons, neuronal dif-
ferentiation, and programed cell death (112). PET studies using
(R)[11C]PK11195 (95, 113) have found microglial activation in
schizophrenia, in addition to post-mortem studies demonstrat-
ing increased density and activation of microglia, though some
of these studies have yielded conflicting evidence (112). Activated
microglia have increased levels of the translocator protein (TPSO)
located at the mitochondrial membrane, and the binding of TPSO
to the (R)[11C]PK11195 is utilized in PET studies as a mea-
sure of neuroinflammation, while other PET ligands for activated
microglia are under development (113). Free-water imaging (114)
is another mode of neuroinflammation imaging, and studies using
this novel method have indicated widespread brain inflammation
and early signs of neurodegeneration in first-episode patients with
schizophrenia (115).
Microglia, astrocytes, and the kynurenine pathway
Activated microglia have many important functions besides
phagocytosis, including cytokine production (IL-1β, IL-12, and
TNF-α) (94, 111), most importantly crosstalk with the serotonin
and glutamate neurotransmitter systems, involving the kynure-
nine pathway (116). Activated microglia also induce functional
changes in brain astrocytes, which release IL-6, IL-10, and TGF-β
(94). In the presence of pro-inflammatory cytokines, e.g., IFN-
γ and TNF-α, tryptophan catabolism to kynurenins in microglia
and astrocytes is induced, resulting in the production of quino-
linic acid (QUIN) in microglia and KYNA in astrocytes. QUIN
is an NMDA agonist and potentially excitotoxic, while KYNA is
an NMDA antagonist and also blocks the α7 nicotinic acetyl-
choline receptor (α7nAChR) (94, 116). Figure 1 summarizes
major points of the activated inflammatory responses in schiz-
ophrenia. The demonstration of elevated levels of KYNA in the
cerebrospinal fluid (CSF) of patients with schizophrenia by two
independent groups (117, 118) in 2001 boosted research in brain
inflammatory-related processes implicated in schizophrenia. Ele-
vation of KYNA in the CSF and prefrontal cortex in patients
with schizophrenia is now an established finding, and is prob-
ably a consequence of peripheral inflammation according to a
recent review by Schwarcz et al. (119). Elevated levels of KYNA are
associated with decreased cognitive performance in animal mod-
els, including altered pre-pulse inhibition of the auditory startle
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FIGURE 1 | Characteristics, sources, and neuronal consequences of
activated inflammatory responses in schizophrenia. Abnormal
expression of inflammatory genes in monocytes/macrophages (M/M)
results in peripheral low-grade inflammation (patients: solid orange and
green lines-healthy subjects: dashed lines). Stress and/or pathogen
exposure may lead to an over-activation of microglia (MG), which activates
astrocytes (AC) and the consequent release of cytokines (IL-6, IL-10, TGF-β)
that stimulate the production of kynurenic acid (KYNA). KYNA blocks
signaling at the NMDA receptor and the α7 nicotinic acetylcholine receptor
(α7nAChR). MGs releases cytokines (IL-1β, IL-12, TNF-α) that weaken the
biosynthesis of serotonin and promotes the production of quinolinic acid
(QUIN) and 3-hydroxykynurenine (3-OHKY), both neurotoxic substances.
Abnormal HPA axis function may further contribute to the development of
low-grade inflammation as the normal feed-back exerted by cortisol is not
working properly. Furthermore, prenatal immune priming by in utero
exposure to infection may provide a developmental source of long-term
immune abnormalities to schizophrenia. With permission from Meyer et al.
(84).
response, deficits of working memory, and attentional set-shifting
paradigms (120, 121), while reducing KYNA resulted in improved
cognitive performance in a wide range of tasks (121). Adding to
this, the kynurenic pathway also offers a possible explanation of
how stress induces psychotic symptoms and cognitive dysfunction
in schizophrenia by linking increased levels of glucocorticoids to
the production of kynurenine in liver, subsequently converted to
KYNA in the brain (121). The kynurenic pathway offers several
potential drug targets for the reduction of brain KYNA levels,
which could improve cognitive function in schizophrenia. Can-
didate pharmacological agents related to schizophrenia treatment
block, e.g., the enzyme kynurenine aminotransferase (KAT), which
transforms kynurenine into KYNA. Most KYNA-lowering drugs
still lack behavioral data (122), while cerebrolysin, a peptider-
gic drug manufactured from purified porcine brain preparations,
which lower brain tissue KYNA levels in vitro (123) also have
been found to improve cognition (124). Interestingly, in a double
blind RCT of patients with schizophrenia cerebrolysin (intra-
venous infusion) as add-on treatment to risperidone was found
to improve scores at the Wechsler Adult Intelligence Scale and
the Wechsler Memory Scale (124). Cerebrolysin is generally well-
tolerated (125) and has also demonstrated pro-cognitive effects
in patients with dementia (126, 127) and traumatic brain injury
(128). In another recent study, d-cycloserine (DSC), a partial ago-
nist at the glycine site of the NMDA receptor, was also found to
reduce the levels of KYNA in human post-mortem frontal cortex
homogenates by dose-dependently blocking KAT (129). DSC has
also been found to improve memory consolidation and to reduce
delusions in combination with cognitive behavioral therapy (130).
IL-1β, S100B, BDNF
In addition to elevated KYNA/QUIN, other aspects of an acti-
vated brain immune system can also have clinically important
effects in schizophrenia. The proinflammatory cytokine IL-1β
has been linked to glutamatergic excitotoxicity (131), and close
dynamic interactions between IL-1β and the NMDA receptor
was the recently demonstrated (132). Pro-inflammatory cytokines
(e.g., IL-1) are also candidate causal agents implicated in the cere-
bral myelin damages discussed above, see (133, 134). The protein
S100B, produced by astrocytes, is a marker of astrocyte activa-
tion. Serving as an example of the pleiotropic effects associated
with many inflammatory factors at low concentration, S100B has
beneficial effects, limiting microglia activation, stress-related neu-
ronal damage, and increase glutamate uptake by astrocytes, while
at higher concentration it has detrimental effects, including induc-
tion of microglial TNF-α secretion and induced production of, e.g.,
COX2/PGE-2, IL-1β, etc. (135). A meta-analysis concluded that
serum levels of S100B may be elevated in schizophrenia, and dis-
ruptions of the blood–brain barrier (BBB) and/or active secretion
by astrocytes were suggested as possible causes (136).
The neurotrophin BDNF is among the substances secreted by
immune cells during inflammation and immune responses (137),
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and an inverse relationship between levels of BDNF and certain
cytokines has been found (138). BDNF has been implicated in
widespread processes relevant to the pathophysiology of schiz-
ophrenia including neurodevelopment, synapse regulation, and
neuroplasticity, as well as effects on cognition, see for example
(138–140). BDNF has been found to be reduced in schizophrenia
in both drug-naïve and chronic patients, although findings are not
entirely consistent across studies. Furthermore, an association has
been found between reduced neurocognitive function and reduced
serum BDNF levels (139). BDNF interacts with dopaminergic,
glutamatergic, and serotonergic systems in the brain, see Nurjono
et al. (138) for a recent update. Regarding BDNF as a drug target,
FGAs have been reported to lower peripheral BDNF, whereas SGAs
either have no effect or increase BDNF, while antidepressants have
been shown to increase BDNF (140).
STRUCTURAL AND FUNCTIONAL CORRELATES OF INFLAMMATORY
DISTURBANCES IN PATIENTS WITH SCHIZOPHRENIA
Structural brain alterations associated with immune-related
genetic polymorphisms were recently reviewed by Fineberg and
Ellman (107). The review identified associations between variabil-
ity in the IL-1 gene complex and white and gray matter volume
reductions in temporal and frontal brain regions, together with
enlarged ventricles in patients with schizophrenia. Furthermore,
this review discussed associations of IL-1 gene variations with
decreased dorsolateral prefrontal function during different neu-
rocognitive tasks (107). In another review, Meyer (105) found
evidence for a positive correlation between the severity of cog-
nitive deficits and the peripheral levels of IL-1β, IL-6, TNF-α,
CRP, and S100B. While the correlation of the inflammatory dis-
turbances with specific cognitive effects is not clarified in patients
with schizophrenia, findings from animal studies and studies in
non-schizophrenic individuals reveal associations of inflamma-
tory disturbances with executive function, sustained attention, and
working memory according to the review by Meyer et al. (105).
ANTI-INFLAMMATORY EFFECTS OF ANTIPSYCHOTIC DRUGS
Monji et al. (141) recently reviewed studies (mostly in vitro and
animal studies) concerning the capability of antipsychotic drugs to
influence activated microglia. The review identified several studies
showing that antipsychotic drugs significantly reduce the secretion
of TNF-α, nitric oxide, IL-1β, and IL-2 from activated microglia.
Furthermore, some drugs were found to have stronger inhibitory
effects, e.g., risperidone, which inhibited the secretion of several
cytokines from activated microglia more than haloperidol, and
indications of clozapine-specific effects have also been reported.
Moreover, in the context of the kynurenine pathway, one ani-
mal study demonstrated that chronic treatment with antipsychotic
drugs reduces brain KYNA (142). Meyer et al. (94) reviewed the
influence of antipsychotic treatment on peripheral cytokines in
clinical populations and found that antipsychotics reduced the
level of proinflammatory cytokines (IL-1β, IL-6, sIL-6R, TNF-α)
while increasing peripheral production of anti-inflammatory sub-
stances such as (sIL-1RA, sIL-2R and IL-10). Here, SGAs seemed to
have the most pronounced effects and a possible relation between
the ability to normalize immune function and clinical effects were
identified. Brain imaging studies investigating antipsychotic drug
treatment in brain imaging paradigms capable of showing effects
on neuroinflammation (e.g., PET/“free water” MRI) would truly
improve this field of research, but we have not been able to identify
any such studies.
THE EFFECTS OF ANTI-INFLAMMATORY/IMMUNE-MODULATING
DRUGS IN THE TREATMENT OF SCHIZOPHRENIA
Non-steroid anti-inflammatory drugs
Based on the notion of activated immune responses in the brain
and/or peripheral tissues, a few clinical studies have evaluated the
effects of non-steroid anti-inflammatory drugs (NSAIDs) in schiz-
ophrenia. The pooled effects size in reducing total Positive and
Negative Syndrome Scale (PANSS) score according to a recent
meta-analysis of the effect of add-on treatment with NSAIDs
[eight studies, two with aspirin (n= 270), six with celecoxib
(n= 504)] to different antipsychotics showed non-significant ben-
efit over placebo (143). Treatment with aspirin alone was superior
to placebo, while treatment with celecoxib was not; these conclu-
sions were also drawn in a meta-analysis of Sommer et al. (144).
When the studies were categorized according to disease phase,
the pooled analyses of all eight studies revealed positive effects of
NSAIDs vs. placebo for first-episode patients. The authors con-
cluded that the present data do not lend significant support to
NSAIDs as add-on therapy to antipsychotic treatment for patients
with schizophrenia. Another review agreed that indiscriminately
suppressing inflammation seems not to be the optimal way of
treating immunological disturbances associated with schizophre-
nia, and that treatment should aim at reversing glial loss, upreg-
ulating beneficial microglial activation and proliferation (MAP)
together with other neuroprotective measures, while ideally down-
regulating harmful aspects of MAP (135). At present, studies more
precisely aiming to elucidate the putative pro-cognitive effects of
treatment with NSAIDs in patients with schizophrenia are lack-
ing, although non-significant effects were demonstrated in a small
study (145).
Erythropoietin
Erythropoietin (EPO) is a cytokine with several identified func-
tions in the brain (146). In a 12-week, placebo-controlled study
(n= 39) with stable schizophrenia patients, treatment with recom-
binant human EPO (40000 IU/week) improved neurocognitive
function compared to placebo in the domains of delayed mem-
ory, language-semantic fluency, attention and perseverative errors
(147). An evaluation of gray matter development in the same study
showed that gray matter loss was significantly less pronounced
in the group treated with EPO (148). Animal studies have sup-
ported a pro-cognitive effect of EPO treatment (146). A systematic
review identified multiple putative beneficial brain targets of EPO
treatment, e.g., modulation of inflammation, neuroprotection,
neurotransmission regulation, effects on BBB permeability, but
the use of EPO can be limited by adverse effects such as thrombo-
sis and cancer (149). EPO has also been found to improve cognitive
function in studies of patients with Parkinson’s disease (150) and
multiple sclerosis (151).
Minocycline
The tetracycline antibiotic drug minocycline has also been tested
as an add-on treatment for patients with schizophrenia, based on
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evidence from animal studies that showed minocycline to have
multiple actions including inhibition of microglial activation and
the attenuation of adaptive immunity through the reduction of
activity and expression of matrix metalloproteinases (MMPs).
MMPs enable T-cells to migrate through the BBB by altering its
permeability, a process associated with myelin degradation (152).
In a placebo-controlled, 6-month trial in patients with schizophre-
nia (54 patients receiving 200 mg minocycline and 26 patients
receiving placebo), cognitive function (and negative symptoms)
improved significantly in the minocycline-treated group, partic-
ularly in the domains of working memory, cognitive flexibility,
and planning (153). Chaudry et al. (154) reported the results of
a 1-year RCT of 155 early schizophrenia patients performed in
Brazil and Pakistan, where minocycline reduced negative symp-
toms (adjusted difference 95% confidence interval 1.55–5.51 at
the PANSS negative subscale), but no significant effects of treat-
ment were found in tests for cognitive function. The meta-analysis
of Sommer et al. (144) identified four RCT studies with n= 182
patients given minocycline, and n= 166 on placebo, the effects on
cognition were not reported, but no significant effects on overall
symptom severity were identified.
Additional drugs with anti-inflammatory action as add-on
treatments for patients with schizophrenia
The meta-analysis by Sommer et al. (144) also investigated the
effect of additional anti-inflammatory treatments. The outcome
measure was the mean change in PANSS (155) or the Brief
Psychiatric Rating Scale (156), and significant improvements of
treatment with n-acetylcysteine (n= 140), aspirin (n= 270), and
estrogens (n= 262) were identified, while studies with davunetide
and PUFAs (eicosapentanoic acid and docosahexanoic acids) did
not show significant effects.
SUMMING UP PRO-COGNITIVE EFFECTS OF
IMMUNOMODULATING/ANTI-INFLAMMATORY DRUG TREATMENT FOR
PATIENTS WITH SCHIZOPHRENIA: CRITICAL METHODOLOGICAL
PROBLEMS REMAIN
The involvement of inflammatory/immunological factors in the
pathophysiology of a large portion of patients with schizophre-
nia is well established through different lines of research, and
data point to several links between these factors and cogni-
tive dysfunction. Presently, many drugs with anti-inflammatory
or immunomodulatory action have been tested (as add-on to
antipsychotic treatment) for patients with schizophrenia, and
while some have shown positive effects for global schizophrenia
symptoms, the effects on cognition were not possible to assess in
the recent meta-analysis by Sommer et al. (144), as only 5 of 26
included studies reported data on cognitive tests and the hetero-
geneity of the cognitive tasks made it impossible to quantitatively
review the effects. Furthermore, as highlighted by Sommer et al.
the drugs tested that were shown to improve the symptoms of
schizophrenia (N -acetylcysteine, estrogens, aspirin) have broad
mechanisms of action, and it is not at all demonstrated that the
improved symptoms are caused by anti-inflammatory actions.
A further critical question to address in future drug research will
be to establish reliable brain imaging methods to quantitatively
assess neuroinflammation, as the levels of peripheral cytokines are
only an indirect measure of brain neuroinflammation. PET stud-
ies with new ligands that specifically target activated microglia
and the “free-water” MRI scanning seem promising, but extensive
development remains before these methods are ready as outcome
measures in drug discovery studies.
SUMMARY AND CONVERGENCE
At present, pharmacological treatment of schizophrenia relies on
antipsychotic drugs, which predominantly relieve positive psy-
chotic symptoms and have little effect on the cognitive dys-
functions restricting the functional level of patients. However,
recent developments in brain imaging, including novel specific
PET ligands and MRI paradigms specifically investigating myelin
integrity, neurotransmitter levels, and neuroinflammation, facili-
tate the unraveling of mechanisms underlying cognitive dysfunc-
tion in schizophrenia. Accumulating evidence supports a com-
bined model including all these areas of pathology underlying
the cognitive deficits in schizophrenia, schematically exemplified
by Figure 2 for the interplay between prefrontal cortex, striatum,
and brain stem. This joint model represents several potential pro-
cognitive drug targets at the level of neurotransmitters, lipids,
and inflammatory markers, however, no current drugs aimed at
these targets are so far definitely proven to be clinically useful as
pro-cognitive drugs for patients with schizophrenia. Studies con-
cerning immunomodulatory drugs, including EPO, minocycline,
celecoxib, aspirin, estrogens, n-acetylcysteine have shown promis-
ing results in single studies, but have not yielded straightforward
support for the use in clinical practice to enhance cognition.
FUTURE PERSPECTIVES
Drugs that would reduce brain levels of KYNA (e.g., KAT
inhibitors) are expected to improve cognitive dysfunctions in
schizophrenia based on animal studies, but remain to be devel-
oped for clinical use. The possibility of pro-cognitive effects of
drugs that have been used to treat other medical conditions for
years, e.g., EPO, minocycline, and aspirin is attractive, also because
the safety profile of many of these drugs are well known in neu-
rological patients populations, reducing the costs of introducing
the drugs as cognitive enhancers for schizophrenia patients. Sev-
eral critical questions currently constraining progress remain to
be solved, however. Firstly, uniformly accepted and standardized
cognitive assessments for repeated measures must be agreed on
for pro-cognitive drug studies in schizophrenia patients. Secondly,
the refinement of brain imaging methods unto sufficient reliabil-
ity and specificity (e.g., measuring neuroinflammation and myelin
integrity) for use as outcome measures in pro-cognitive drug is
essential for studies of putative cognition enhancers in humans.
Thirdly, and at least of prominent importance in the field of further
developments of pro-cognitive glutamatergic substances are the
problems of translating findings in animal studies to human drug
treatment.
However, even though the process of developing novel phar-
macological agents is highly sophisticated, identifying novel treat-
ment targets through thorough clinical and preclinical studies
remains pivotal in the continued search for improved treatment
of schizophrenia. The convergence of a disordered inflammatory
system, disturbances in myelination/oligodendrocyte function,
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FIGURE 2 | Simplified putative interplay between selected
neurotransmitters, oligodendrocytes, and inflammation in the
pathology of cognitive dysfunctions in schizophrenia. Green
cell=excitatory pyramidal glutamatergic (GLU) neuron; red cell= inhibitory
GABAergic (GABA) interneuron; blue cell=modulatory dopaminergic (D)
neuron; light blue cell=oligodendrocyte (O) with white myelin sheets
enclosing the pyramidal cell axon; KYNA= kynurenic acid,
QUIN=quinolinic acid. The figure displays some putative points of
convergence between neurotransmitters, myelin, and neuroinflammation
relevant to the cognitive dysfunctions of schizophrenia. Details are
elaborated in the text. (1) In the prefrontal cortex, abnormal NMDA
functioning on, and/or deficient GABA release and reuptake in a subset of
GABAergic interneurons result in deficient negative feedback on pyramidal
glutamatergic neurons, which may lead to glutamatergic hyperactivity,
excitotoxicity, and disruption of coordinated firing of pyramidal cells. (2)
Deficient glutamatergic neuronal activity leads to decreased excitatory
input on GABAergic interneurons terminating on dopaminergic projections
to striatum, leading to striatal hyperdopaminergia. The hyperdopaminergia
may inversely influence cognitive functions located in the prefrontal
cortex. (3) Reduced myelin integrity may inversely influence glutamatergic
signaling leading to the same consequences as in the point above.
Oligodendrocytes express NMDA receptors and are thus vulnerable for
excitotoxicity from excess glutamate and QUIN. (4) During inflammation
QUIN is produced in microglia and KYNA in astrocytes. QUIN is an NMDA
agonist and potentially excitotoxic, while KYNA is an NMDA antagonist
that could induce cognitive dysfunctions consistent with the NMDA
receptor hypofunction hypothesis of schizophrenia. Adapted with
permission from Lisman et al. (72) and Takahashi et al. (102).
and transmitter dysfunctions in schizophrenia open new paths
for pro-cognitive drug discovery with putative large functional
improvements to be achieved for patients with schizophrenia.
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